Estrella Immunopharma Inc
ESLA
NASDAQ
Biotechnology
$0.72
USD
0.00 (-0.19%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $31.18M
Volume 9.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-13.25M
TTM
-118.6%
YoY
Operating Cash Flow
$-8.02M
TTM
-1323.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 0.7 | 0.9 | 0.6 | 0.6 | 0.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.1 | 5.5 | 4.8 | 0.6 | 2.3 |
Operating Income | -2.1 | -5.5 | -4.8 | -0.6 | -2.3 |
EBITDA | -2.1 | -5.5 | -4.8 | -0.6 | -2.3 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Income Before Income Taxes | -2.1 | -5.5 | -4.8 | -0.6 | -2.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | -0.0 | 0.0 |
Net Income | -2.1 | -5.5 | -4.8 | -0.6 | -2.3 |
Consolidated Net Income / Loss | -2.1 | -5.5 | -4.8 | -0.6 | -2.3 |
Net Income Attributable to Common Shareholders | -2.1 | -5.5 | -4.8 | -0.6 | -2.3 |
Basic EPS | -$0.06 | -$0.15 | -$0.13 | -$0.02 | -$0.05 |
Diluted EPS | -$0.06 | -$0.15 | -$0.13 | -$0.02 | -$0.05 |
Basic Shares Outstanding | 36.2M | 36.2M | 37.1M | 37.8M | 42.1M |
Diluted Shares Outstanding | 36.2M | 36.2M | 37.1M | 37.8M | 42.1M |